Summary:

BRAF-mutant cancers have been knocked down by BRAF and MEK inhibitor combos, yet the cancers always find a way to get back up. Adding a third medicine, namely, a dimer-selective BRAF inhibitor, can knock down longer and better.

See related article by Adamopoulos et al., p. 1716.

©2021 American Association for Cancer Research
2021
American Association for Cancer Research.
You do not currently have access to this content.